XERS - Xeris Biopharma Holdings, Inc.
IEX Last Trade
2.9
0 0%
Share volume: 520,716
Last Updated: Tue 24 Dec 2024 06:22:30 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.51%
PREVIOUS CLOSE
CHG
CHG%
$2.90
0.53
0.15%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-10 | 2022-11-09 | 2023-03-08 | 2023-05-09 | 2023-08-08 | 2023-11-09 | 2024-03-06 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 318.616 M | 303.017 M | 344.522 M | 321.360 M | 328.778 M | 327.784 M | 322.602 M | 336.616 M | |
| Current Assets | 161.206 M | 148.919 M | 186.818 M | 165.513 M | 155.741 M | 158.051 M | 156.264 M | 173.280 M | |
| Inventories | 17.887 M | 20.121 M | 24.735 M | 29.039 M | 36.538 M | 38.143 M | 38.838 M | 40.878 M | |
| Other Current Assets | 6.010 M | 7.847 M | 9.287 M | 10.512 M | 8.310 M | 7.967 M | 5.778 M | 7.636 M | |
| Short Term Investments | 6.010 M | 7.847 M | 9.287 M | 10.512 M | 8.310 M | 7.967 M | 5.778 M | 7.636 M | |
| Total Receivables | 25.756 M | 27.518 M | 30.830 M | 30.860 M | 30.225 M | 45.966 M | 39.197 M | 37.414 M | |
| Current Cash | 111.553 M | 93.433 M | 121.966 M | 95.102 M | 80.668 M | 65.975 M | 72.451 M | 87.352 M | |
| Total Non-current Assets | 157.410 M | 154.098 M | 157.704 M | 155.847 M | 173.037 M | 169.733 M | 166.338 M | 163.336 M | |
| Property Plant Equipment | 6.170 M | 5.751 M | 5.516 M | 6.477 M | 6.552 M | 6.185 M | 5.971 M | 5.783 M | |
| Other Assets | 2.352 M | 2.170 M | 8.722 M | 8.615 M | 28.440 M | 28.214 M | 27.744 M | 27.641 M | |
| Intangible Assets | 126.029 M | 123.318 M | 120.607 M | 117.896 M | 115.186 M | 112.475 M | 109.764 M | 107.053 M | |
| Goodwill | 22.859 M | 22.859 M | 22.859 M | 22.859 M | 22.859 M | 22.859 M | 22.859 M | 22.859 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 318.616 M | 303.017 M | 344.522 M | 321.360 M | 328.778 M | 327.784 M | 322.602 M | 336.616 M | |
| Total liabilities | 244.673 M | 247.977 M | 299.335 M | 291.312 M | 315.137 M | 323.919 M | 329.384 M | 345.794 M | |
| Total current liabilities | 64.545 M | 68.558 M | 73.621 M | 81.423 M | 79.678 M | 87.039 M | 95.193 M | 73.084 M | |
| Accounts Payable | 6.631 M | 3.916 M | 4.606 M | 11.983 M | 11.621 M | 12.078 M | 11.565 M | 7.094 M | |
| Other liabilities | 37.865 M | 37.056 M | 25.719 M | 9.402 M | 9.563 M | 8.799 M | 6.227 M | 6.064 M | |
| Current long term debt | 0.000 | 0.000 | 1.580 M | 1.448 M | 1.935 M | 2.366 M | 3.495 M | 4.624 M | |
| Long term debt | 138.068 M | 138.507 M | 196.477 M | 196.969 M | 223.053 M | 225.577 M | 225.696 M | 264.071 M | |
| Other liabilities | 37.865 M | 37.056 M | 25.719 M | 9.402 M | 9.563 M | 8.799 M | 6.227 M | 6.064 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 73.943 M | 55.040 M | 45.187 M | 30.048 M | 13.641 M | 3.865 M | -6.782 M | -9.178 M | |
| Common stock | 135.530 M | 135.952 M | 136.000 M | 137.143 M | 137.338 M | 138.060 M | 138.159 M | 140.514 M | |
| Retained earnings | -520.009 M | -541.840 M | -554.770 M | -571.604 M | -591.446 M | -603.635 M | -617.025 M | -636.005 M |